Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06450067Recruiting
Inaticabtagene Autoleucel for Relapsed or Refractory ALL
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07755761Recruiting
Tube surgery for hard-to-treat glaucoma
This study tests a new tube-based surgery to lower eye pressure in people with advanced or difficult-to-treat open-angle glaucoma. The goal is to see if this surgery works better than standard care for controlling pressure and preserving vision.
BanhāAges 18 years+ - NCT07742215RecruitingPhase 3
Combination treatment for relapsed or refractory multiple myeloma
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
HomyelAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT04010526RecruitingPhase 2
Local treatment for Crohn’s fistulas using your own fat cells
This Phase 2 trial studies whether a local injection of fat-derived cells (made from your own tissue) can improve difficult Crohn’s disease fistulas around the anus. It’s designed for people whose Crohn’s fistulas have not responded to usual treatments.
Marseille, PACAAges 18 years+ - NCT07725380RecruitingPhase 1/Phase 2
Two drugs for relapsed sarcoma or osteosarcoma
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Tampa, FloridaAges 12–40 - NCT06543979RecruitingPhase 1/Phase 2
Anorectal manometry for children with chronic constipation
This study is for children aged 4–16 who have long-term constipation that doesn't get better with standard laxatives. It uses a test called anorectal manometry to measure how well the muscles in the bottom work, which can help guide treatment.
CairoAges 4–16 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07715136RecruitingPhase 1
BCMA-CD19 CAR-T for Refractory Inflammatory Myopathy
This trial tests a new type of cell therapy (BCMA-CD19 cCAR-T) for people with inflammatory myopathy that hasn't improved with standard treatments. The goal is to see if this treatment can help control the disease.
Chengdu, SichuanAges 18–60 - NCT07715630RecruitingPhase 1
PICX CAR-T therapy for relapsed or hard-to-treat multiple myeloma
This trial tests a new treatment called PICX CAR-T, a type of immune cell therapy, for multiple myeloma that has come back or not responded well to at least two prior treatments. It aims to see if this therapy can help control the disease.
Kunming, YunnanAges 18 years+ - NCT07717281Recruiting
Studying nerve-muscle organoids for refractory myasthenia gravis
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
MilanAges 18 years+ - NCT07722754RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18–75 - NCT07716930Enrolling by invitation
Eye scan study for drug-resistant epilepsy
This study uses a special eye scan (OCT) to look for changes in the retina that might be linked to hard-to-control epilepsy. The goal is to find new biomarkers that could help doctors better understand and manage the condition.
IstanbulAges 18–40 - NCT07721142RecruitingPhase 4
Chinese medicine and Western medicine for hard-to-treat rheumatoid arthritis
This trial combines traditional Chinese herbal medicine with standard Western treatments for people with rheumatoid arthritis that hasn't responded well to at least two prior medications. It aims to see if the combination is more effective and safe.
ShanghaiAges 18–70 - NCT05299424RecruitingPhase 1/Phase 2
CM336 for multiple myeloma after prior treatments
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05845255Recruiting
Test wearable monitoring for epilepsy quality of life and safety
This study tests a wearable device that records seizure-related information to understand how epilepsy affects daily life and safety. It may help your care team better track seizures in real-world settings and understand quality-of-life changes.
KorkAges 12–65 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT07710534RecruitingPhase 2
A study of decitabine-cedazuridine and venetoclax for blood cancers
This trial tests a combination of two drugs (decitabine-cedazuridine and venetoclax) that are given in a low-dose, frequent schedule (metronomic) for people with certain blood cancers that have come back or not responded to treatment. The goal is to see if this combo can help control the disease.
Richmond, VirginiaAges 18 years+ - NCT07714512RecruitingPhase 1/Phase 2
Anti-CD38 antibody for severe aplastic anemia not helped by other treatments
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06642025RecruitingEarly Phase 1
EX02 car-t cells for hard-to-treat acute myeloid leukemia
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
Hefei, AnhuiAges 18–70 - NCT06644443RecruitingPhase 1/Phase 2
BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Shenzhen, GuangdongAges 18–75 - NCT07704424Recruiting
Testing a heart pump for severe right heart failure
This trial is evaluating a new temporary heart pump called CorVad for people who develop severe right heart failure shortly after heart surgery, a heart attack, or a heart transplant. The pump is designed to help the right side of the heart pump blood when medications are not enough.
Hefei, AnhuiAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,200 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.